Biosimilars

A new study found that 83.3% of practitioners believe biosimilars are just as effective and safe as originator drugs. Yet, because of knowledge gaps related to biosimilars, patients fear disease flares caused by biosimilars, as well as the drug’s effectiveness.

Providers identified an increased administrative workload and inadequate biosimilar device training as pain points during a mandatory switch to a biosimilar.

The proposed denosumab biosimilar, SB16, demonstrated pharmacokinetic bioequivalence, as well as equivalent efficacy, safety, and immunogenicity,

Results of a recent systematic review demonstrated no difference in the immunogenicity rates and safety profiles in patients who switched to a biosimilar and those who continued to receive the reference product.

Feldman discusses the importance of self-education and open communication between patient and physician to help stay informed about relevant laws.

Feldman explains how healthcare legislation and regulation play a pivotal role in shaping patient care and costs.

Madelaine Feldman, MD, discusses the role pharmacy benefit managers play in delaying patient care.

Biosimilars to several recognized biologic rheumatoid arthritis treatments are now approved for use in the United States. Test your knowledge with this quiz.

Results demonstrated comparable safety, immunogenicity, and pharmacokinetics between adalimumab-afzb and the reference product.

The biosimilar month in review highlights an interview with leading experts, the latest data regarding switching between biologics and biosimilars, and the efficacy of infliximab biosimilars among patients with inflammatory conditions.

At week 16, no significant differences in response rates were observed regarding the adalimumab biologic and biosimilars.

The indication for the intravenous formulation is for adults with RA, as well as adults and children with either active PJIA or systemic JIA.

The biosimilar was deemed comparable and tolerable in terms of safety between groups.

A trio of healthcare providers offer perspective on educating patients regarding biosimilar and interchangeability.

Phase 3 results show the non-inferior efficacy of biosimilar liraglutide to the originator in lowering HbA1C over 26 weeks of treatment.

Although most clinicians surveyed are unopposed to prescribing adalimumab biosimilars, hesitancies surrounding prescribing practices and an uncertainty of cost savings remains.

A review of Japan post-marketing data support the biosimilar in use for psoriasis, rheumatoid arthritis, Crohn's disease and ulcerative colitis.

Biosimilar infliximab-dyyb proves successful in achieving and maintaining the control of non-infectious uveitis in the study cohort.

A network meta-analysis lends "compelling" support to the practice of switching patients with RA from biologics to less costly biosimilars at 6 months.

More patients who retransitioned to originator infliximab after switching to a biosimilar discontinued infliximab than patients who remained on the biosimilar.

Most patients continued treatment with the adalimumab biosimilar over 2 years, with a treatment retention rate of 73.1%.

A confirmatory efficacy and safety study demonstrated therapeutic equivalence, immunogenicity, pharmacokinetics, and safety of an aflibercept biosimilar.

An analysis of the Phoenix cohort provides insight into responder rates and treatment persistence with infliximab biosimilars among those with no previous exposure to biologics, a previous failure to respond to biologics, or those switching from reference infliximab.

Use of etanercept biosimilars was not associated with an increased likelihood of treatment discontinuation or disease activity among people with rheumatoid arthritis relative to continuing treatment with originator etanercept.

A program from the American Oncology Network shows promise to introducing cost-efficient biosimilar substitution opportunities to prescribers and payors.

An analysis from Taiwan suggest immunogenicity differences are limited between biosimilars approved by the FDA and their reference biologic products.

A switch from a biologic treatment to a biosimilar demonstrated comparable effects for both primary and co-primary outcomes in patients with rheumatoid arthritis.

The approval was based on evidence showing no clinically meaningful differences between natalizumab-sztn and the reference drug in terms of safety, purity, and potency.

Disease activity improved by week 16 in patients receiving CT-P13 and was maintained through the end of the treatment period.

Initial real-world experience with ranibizumab biosimilar agents revealed no unexpected adverse outcomes across 16 retina centers, with similar efficacy to reference ranibizumab.